Abstract | BACKGROUND: METHODS: RESULTS: CONCLUSION: These results suggested that two doses may be enough for a clinical vaccine strategy design using MPL & QS21 adjuvanted recombinant protein, especially in consideration of the limited production capacity of COVID-19 vaccine in a public health emergency.
|
Authors | Zhidong Hu, Jian-Ping Chen, Jin-Chuan Xu, Zhen-Yan Chen, Rong Qu, Ling Zhang, Wenrong Yao, Juan Wu, Heng Yang, Douglas B Lowrie, Yong Liu, Xiao-Yong Fan |
Journal | Virology
(Virology)
Vol. 566
Pg. 56-59
(01 2022)
ISSN: 1096-0341 [Electronic] United States |
PMID | 34864488
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021. Published by Elsevier Inc. |
Chemical References |
- Adjuvants, Immunologic
- Adjuvants, Vaccine
- Antibodies, Neutralizing
- Antibodies, Viral
- Antigens, Viral
- COVID-19 Vaccines
- Drug Combinations
- Lipid A
- Recombinant Proteins
- Saponins
- Spike Glycoprotein, Coronavirus
- Vaccines, Subunit
- adjuvant system 01
- spike protein, SARS-CoV-2
- saponin QA-21V1
- monophosphoryl lipid A
|
Topics |
- Adjuvants, Immunologic
(administration & dosage)
- Adjuvants, Vaccine
(administration & dosage)
- Animals
- Antibodies, Neutralizing
- Antibodies, Viral
(metabolism)
- Antibody Formation
- Antigens, Viral
(immunology)
- COVID-19
(immunology, virology)
- COVID-19 Vaccines
(immunology)
- Dose-Response Relationship, Immunologic
- Drug Combinations
- Female
- HEK293 Cells
- Humans
- Immunization
- Immunogenicity, Vaccine
- Lipid A
(administration & dosage, analogs & derivatives, immunology)
- Mice, Inbred BALB C
- Recombinant Proteins
(administration & dosage, immunology)
- SARS-CoV-2
(immunology)
- Saponins
(administration & dosage, immunology)
- Spike Glycoprotein, Coronavirus
(immunology)
- Vaccines, Subunit
(immunology)
- Mice
|